INmune Bio, Inc. Announces Data on Its Lead Compound Which Highlights the Potential to Lower the Risk of Alzheimer’s Disease in Obese Individuals (EIN Newsdesk)

INmune Bio, Inc. Announces Data on Its Lead Compound Which Highlights the Potential to Lower the Risk of Alzheimer’s Disease in Obese Individuals

INmune Bio, Inc., an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced the publication of new positive data in the journal Alzheimer’s Research & Therapy. The data highlights INmune Bio’s lead compound, XPro1595, as a potentially effective therapy to lower the risk for Alzheimer’s disease in obese individuals.

“Our new data suggest that high fructose and high caloric diets impact insulin signaling and immune-metabolic interactions increasing the risk for neurodegenerative conditions such as Alzheimer’s disease,” said Malú Tansey, Ph.D., professor of neuroscience and director of the Center for Translational Research in Neurodegenerative Disease at the University of Florida College of Medicine and the corresponding author of this peer-reviewed publication. “These new data suggest that XPro1595 may have therapeutic potential to block various features of Alzheimer’s-like pathology in mice.”

Learn more about INmune Bio, Inc. Announces Data on Its Lead Compound Which Highlights the Potential to Lower the Risk of Alzheimer’s Disease in Obese Individuals.
X